|
1
|
Zhu G, Lin JC, Kim SB, Bernier J, Agarwal
JP, Vermorken JB, Thinh DHQ, Cheng HC, Yun HJ, Chitapanarux I, et
al: Asian expert recommendation on management of skin and mucosal
effects of radiation, with or without the addition of cetuximab or
chemotherapy, in treatment of head and neck squamous cell
carcinoma. BMC Cancer. 16(42)2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6(92)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jicman Stan D, Niculet E, Lungu M, Onisor
C, Rebegea L, Vesa D, Bezman L, Bujoreanu FC, Sarbu MI, Mihailov R,
et al: Nasopharyngeal carcinoma: A new synthesis of literature data
(review). Exp Ther Med. 23(136)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kang H, Kiess A and Chung CH: Emerging
biomarkers in head and neck cancer in the era of genomics. Nat Rev
Clin Oncol. 12:11–26. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Marur S and Forastiere AA: Head and neck
squamous cell carcinoma: Update on epidemiology, diagnosis, and
treatment. Mayo Clin Proc. 91:386–396. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Boussios S, Seraj E, Zarkavelis G,
Petrakis D, Kollas A, Kafantari A, Assi A, Tatsi K, Pavlidis N and
Pentheroudakis G: Management of patients with recurrent/advanced
cervical cancer beyond first line platinum regimens: Where do we
stand? A literature reviews. Crit Rev Oncol Hematol. 108:164–174.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Peng PJ, Lv BJ, Wang ZH, Liao H, Liu YM,
Lin Z, Con YY and Huang PY: Multi-institutional prospective study
of nedaplatin plus S-1 chemotherapy in recurrent and metastatic
nasopharyngeal carcinoma patients after failure of
platinum-containing regimens. Ther Adv Med Oncol. 9:68–74.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tsai MH, Chuang HC, Lin YT, Yang KL, Lu H,
Huang TL, Tsai WL, Su YY and Fang FM: The prognostic value of
preoperative albumin to alkalin phosphatase ratio on survival
outcome for patients with locally advanced oral squamous cell
carcinoma. Technol Cancer Res Treat.
21(15330338221141254)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lubov J, Labbe M, Sioufi K, Morand GB,
Hier MP, Khanna M, Sultanem K and Mlynarek AM: Prognostic factors
of head and neck cutaneous squamous cell carcinoma: A systematic
review. J Otolaryngol Head Neck Surg. 50(54)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nwabudike LC and Tatu AL: Reply to
Gambichler T et al: Altered epigenetic pathways and cell
cycle dysregulation in healthy appearing skin of patients with
koebnerized squamous cell carcinomas following skin surgery. J Eur
Acad Dermatol Venereol. 33:e3–e4. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu GFF, Ranck MC, Solanki AA, Cao H,
Kolokythas A, Wenig BL, Chen L, Ard S, Weichselbaum RR, Halpern H
and Spiotto MT: Racial parities in outcomes after radiotherapy for
head and neck cancer. Cancer. 120:244–252. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wiser I, Scope A, Azriel D, Zloczower E,
Carmel NN and Shalom A: Head and Neck cutaneous squamous cell
carcinoma clinicopathological risk factors according to age and
gender: A Population-based Study. Isr Med Assoc J. 18:275–278.
2016.PubMed/NCBI
|
|
13
|
Wang G, Zhang M, Cheng M, Wang X, Li K,
Chen J, Chen Z, Chen S, Chen J, Xiong G, et al: Tumor
microenvironment in head and neck squamous cell carcinoma:
Functions and regulatory mechanisms. Cancer Lett. 507:55–69.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Alsahafi E, Begg K, Amelio I, Raulf N,
Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and
neck cancer: Molecular biology and ongoing challenges. Cell Death
Dis. 10(540)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mesia R, Iglesias L, Lambea J,
Martinez-Trufero J, Soria A, Taberna M, Trigo J, Chaves M,
Garcia-Castano A and Cruz J: SEOM clinical guidelines for the
treatment of head and neck cancer (2020). Clin Transl Oncol.
23:913–921. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Burr A, Harari P, Wieland A, Kimple R,
Hartig G and Witek M: Patterns of failure for hypopharynx cancer
patients treated with limited high dose radiotherapy treatment
volumes. Radiat Oncol J. 40:225–231. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kao HF, Huang HC, Liao BC and Hong RL:
Shourt-course pembrolizumab and continuous afatinib therapy for
recurrent or metastatic head and neck squamous cell carcinoma: A
real-world data analysis. BMC Cancer. 22(1228)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jung K, Narwal M, Min SY, Keam B and Kang
H: Squamous cell carcinoma of head and neck: What internists should
know. Korean J Intern Med. 35:1031–1044. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Koh J, Walsh P, D'Costa I and Bhatti O:
Head and neck squamous cell carcinoma survivorship care. Aust J Gen
Pract. 48:846–848. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kitamura N, Sento S, Yoshizawa Y, Sasabe
E, Kudo Y and Yamamoto T: Current trends and future prospects of
molecular targeted therapy in head and neck squamous cell
carcinoma. Int J Mol Sci. 22(240)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vasconcelos L, Melo JC, Miot HA, Marques
ME and Abbade LP: Invasive head and neck cutaneous squamous cell
carcinoma: Clinical and histopathological characteristics,
frequency of local recurrence and metastasis. An Bras Dermatol.
89:562–568. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Oliva M, Spreafico A, Taberna M, Alemany
L, Coburn B, Mesia R and Siu LL: Immune biomarkers of response to
immune-checkpoint inhibitors in head and neck squamous cell
carcinoma. Ann Oncol. 30:57–67. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kraft S and Granter SR: Molecular
pathology of skin neoplasms of the head and neck. Arch Pathol Lab
Med. 138:759–787. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang J, Chen X, Tian Y, Zhu G, Qin Y, Chen
X, Pi L, Wei M, Liu G, Li Z, et al: Six gene signature for
predicting survival in patients with head and neck squamous cell
carcinoma. Aging (Albany NY). 12:767–783. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rahman S, Kraljević Pavelić S and
Markova-Car E: Circadian (de)regulation in head and neck squamous
cell carcinoma. Int J Mol Sci. 20(2662)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zeng S, Fu L, Zhou P and Ling H:
Identifying risk factors for the prognosis of head and neck
cutaneous squamous cell carcinoma: A systematic review and
meta-analysis. PLoS One. 15(e0239586)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ali SR, Strafford H, Dobbs TD,
Fonferko-Shadrach B, Lacey AS, Pickrell WO, Hutchings HA and
Whitaker IS: Development and validation of an automated basal cell
carcinoma histopathology information extraction system using
natural language processing. Front Surg. 9(870494)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dika E, Scarfì F, Ferracin M, Broseghini
E, Marcelli E, Bortolani B, Campione E, Riefolo M, Ricci C and
Lambertini M: Basal cell carcinoma: A comprehensive review. Int J
Mol Sci. 21(5572)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Szewczyk M, Pazdrowski J, Pabiszczak M,
Wieckowska B, Danczak-Pazdrowska A and Golusinski W: Local
recurrence risk in head and neck basal cell carcinoma. Otolaryngol
Pol. 76:1–5. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shavlokhova V, Vollmer M, Gholam P, Saravi
B, Vollmer A, Hoffmann J, Engel M and Freudlsperger C: Deep
learning on basal cell carcinoma in vivo reflectance confocal
microscopy data. J Pers Med. 12(1471)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yang X, Ren H, Guo X, Hu C and Fu J:
Radiation-induced skin injury: Pathogenesis, treatment, and
management. Aging (Albany NY). 12:23379–23393. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bertino G, Muir T, Odili J, Groselj A,
Marconato R, Curatolo P, Kis E, Lonkvist CK, Clover J, Quaglino P,
et al: Treatment of basal cell carcinoma with electrochemotherapy:
Insights from the InspECT Registry (2008-2019). Curr Oncol.
29:5324–5337. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Farah CS: Molecular landscape of head and
neck cancer and implications for therapy. Ann Transl Med.
9(915)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yulek O, Batur S, Ozcan K, Yol C and Aydın
Ülgen Ö: Relationship between PD-L1 expression and prognostic
factors in high-risk cutaneous squamous and basal cell carcinoma.
Bosn J Basic Med Sci. 22:894–900. 2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hasan A, Rabie A, Elhussiny M, Nasr M,
Kamel MI, Hegab A, El-Kady AS, Nagaty ME, Seleem A, Abbas M, et al:
Recurrent cutaneous basal cell carcinoma after surgical excision: A
retrospective clinicopathological study. Ann Med Surg (Lond).
78(103877)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kara I, Vural A, Unlu M, San F, Benan
Göçer G and Yildiz MG: Management of basal cell carcinomas:
Clinical experience. Turk Arch Otorhinolaryngol. 60:9–15.
2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kasumagic-Halilovic E, Hasic M and
Ovcina-Kurtovic N: A clinical study of basal cell carcinoma. Med
Arh. 73:394–398. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Castanheira A, Boaventura P, Pais Clemente
M, Soares P, Mota A and Lopes JM: Head and neck cutaneous basal
cell carcinoma: What should the otorhinolaryngology head and neck
surgeon care about? Acta Otorhinolaryngol Ital. 40:5–18.
2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chinem VP and Miot HA: Prevalence of
actinic skin lesions in patients with basal cell carcinoma of the
head: A case-control study. Rev Assoc Med Bras (1992). 58:188–196.
2012.PubMed/NCBI(In English, Portuguese).
|
|
40
|
Otsuka ACVG, Bertolli E, de Macedo AP,
Pinto CAL and Duprat Neto JP: Intraoperative assessment of surgical
margins using ‘en face’ frozen sections in the management of
cutaneous carcinomas. An Bras Dermatol. 97:583–591. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Magnes T, Wagner S, Kiem D, Wiess L,
Rinnerthaler G, Greil R and Melchardt T: Prognostic and predictive
factors in advanced head and neck squamous cell carcinoma. Int J
Sci Mol. 22(4981)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hutchinson MKND, Mierzwa M and D'Silva NJ:
Radiation resistance in head and neck squamous cell carcinoma: Dire
need for an appropriate sensitizer. Oncogene. 39:3638–3649.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zenda S, Ota Y, Tachibana H, Ogawa H,
Ishii S, Hashiguchi C, Akimoto T, Ohe Y and Uchitomi Y: A
prospective picture collection study for a grading atlas of
radiation dermatitis for clinical trials in head-and-neck cancer
patients. J Radiat Res. 57:301–306. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bhatt S, Mandal S, Mehrotra G, Arora V and
Singh U: Multidetector computed tomography perfusion in head and
neck squamous cell carcinomas: Evaluation of a dose reduction
strategy. Indian J Radiol Imaging. 32:451–459. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Haubner F, Ohmann E, Pohl F, Strutz J and
Gassner HG: Wound healing after radiation therapy: Review of the
literature. Radiat Oncol. 7(162)2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ramirez M, Ravichandran S, Ronald L,
Pabon-Ramos WM, Smith TP, Kim CY and Ronald J: Recognition and
management of dermatologic complications from interventional
radiology procedures. Diagn Interv Imaging. 100:659–670.
2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Lecocq M, Poncin A and Sautois B:
Immunotherapy for head and neck squamous cell carcinoma. Rev Med
Liege. 76:398–402. 2021.PubMed/NCBI(In French).
|
|
48
|
Amit M, Takahashi H, Dragomir MP,
Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA,
Cai Y, Wang R, et al: Loss of p53 drives neuron reprogramming in
head and neck cancer. Nature. 578:449–454. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lim KP, Chun NA, Gan CP, Teo SH, Rahman
ZA, Abraham MT, Zain RB, Ponniah S and Cheong SC: Identification of
immunogenic MAGED4B peptides for vaccine development in oral cancer
immunotherapy. Hum Vaccin Immunother. 10:3214–3223. 2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jiang H, Zhou L, Shen N, Ning X, Wu D,
Jiang K and Huang X: M1 macrophage-derived exosomes and their key
molecule lncRNA HOTTIP suppress head and neck squamous cell
carcinoma progression by upregulating the TLR5/NF-κB pathway. Cell
Death Dis. 13(183)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mora Román JJ, Del Campo M, Villar J,
Paolini F, Curzio G, Venuti A, Jara L, Ferreira J, Murgas P,
Lladser A, et al: Immunotherapeutic potential of Mollusk
Hemocyanins in combination with human vaccine adjuvants in murine
models of oral cancer. J Immunol Res. 2019(7076942)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Malonis RJ, Lai JR and Vergnolle O:
Peptide-based vaccines: Current progress and future challenges.
Chem Rev. 120:3210–3229. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Filderman JN and Storkus WJ: Finding the
right help in the tumor microenvironment. J Clin Invest.
132(e161052)2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ferris RL: Immunology and immunotherapy of
head and neck cancer. J Clin Oncol. 33:3293–3304. 2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Albers AE, Qian X, Kaufmann AM, Mytilineos
D, Ferris RL, Hoffmann TK and DeLeo AB: Phenotype of p53 wild-type
epitope-specific T cells in the circulation of patients with head
and neck cancer. Sci Rep. 8(10716)2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Leroux-Roels G: Unmet needs in modern
vaccinology: Adjuvants to improve the immune response. Vaccine. 28
(Suppl 3):C25–C36. 2010.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Chen X, Yang J, Wang L and Liu B:
Personalized neoantigen vaccination with synthetic long peptides:
Recent advances and future perspectives. Theranostics.
10:6011–6023. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Sun Z, Sun X, Chen Z, Du J and Wu Y: Head
and neck squamous cell carcinoma: Risk factors, molecular
alterations, immunology and peptide vaccines. Int J Pept Res Ther.
28(19)2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Calvo Tardón M, Allard M, Dutoit V,
Dietrich PY and Walker PR: Peptides as cancer vaccines. Curr Opin
Pharmacol. 47:20–26. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Bezu L, Kepp O, Cerrato G, Pol J, Fucikova
J, Spisek R, Zitvogel L, Kroemer G and Galluzzi L: Trial watch:
Peptide-based vaccines in anticancer therapy. OncoImmunology.
7(e1511506)2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Shibata H, Zhou L, Xu N, Egloff AM and
Uppaluri R: Personalized cancer vaccination in head and neck
cancer. Cancer Sci. 112:978–988. 2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sakakura K, Takahashi H, Motegi SI,
Yokobori-Kuwabara Y, Oyama T and Chikamatsu K: Immunological
features of circulating monocyte subsets in patients with squamous
cell carcinoma of the head and neck. Clin Immunol.
225(108677)2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Miyazaki A, Kobayashi J, Torigoe T,
Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A,
Michifuri Y, Nakamori K, et al: Phase I clinical trial of
survivin-derived peptide vaccine therapy for patients with advanced
or recurrent oral cancer. Cancer Sci. 102:324–329. 2011.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Idenoue S, Hirohashi Y, Torigoe T, Sato Y,
Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsurama T, Asanuma H, et
al: A potent immunogenic general cancer vaccine that target
survivin, an inhibitor of apoptosis proteins. Clin Cancer Res.
11:1474–1482. 2005.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Farnevo L, Tiefenbock K, Ansell A, Thunell
LK, Garvin S and Roberg K: Strong expression of survivin is
associated with positive response to radiotherapy and improved
overall survival in head and neck squamous cell carcinoma patients.
Int J Cancer. 133:1994–2003. 2013.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Wang C, Zainal NS, Chai SJ, Dickie J, Gan
CP, Zulaziz N, Lye BKW, Sutavani RV, Ottensmeier CH, King EV, et
al: DNA vaccines targeting novel cancer-associated antigens
frequently expressed in head and neck cancer enhance the efficacy
of checkpoint inhibitor. Front Immunol. 12(763086)2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Tseng SH, Liu L, Peng S, Kim J, Ferrall L,
Hung CF and Wu CF: Control of spontaneous HPV16 E6/E7 expressing
oral cancer in HLA-A2 (AAD) transgenic mice with therapeutic HPV
DNA vaccine. J Biomed Sci. 28(63)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wu A, Zeng Q, Kang TH, Peng S, Roosinovich
E, Pai SI and Hung CF: Innovative DNA vaccine for human
papillomavirus (HPV)-associated head and neck cancer. Gene Ther.
18:304–312. 2011.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Abd-Aziz N and Poh CL: Development of
peptide-based vaccines for cancer. J Oncol.
2022(9749363)2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Shiah SG, Chou ST and Chang JY: MicroRNAs:
Their role in metabolism, tumor microenvironment, and therapeutic
implications in head and neck squamous cell carcinoma. Cancers
(Basel). 13(5604)2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Wong TS, Wei G and Chan JY: Interactions
between E-cadherin and microRNA deregulation in head and neck
cancers: The potential interplay. Biomed Res Int.
2014(126038)2014.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Chen D, Cabay RJ, Jin Y, Wang A, Lu Y,
Shah-Khan M and Zhou X: MicroRNA deregulation in head and neck
squamous cell carcinomas. J Oral Maxillofac Res.
4(e2)2013.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Derakhshan A, Chen Z and Van Waes C:
Therapeutic small molecules target inhibitor of apoptosis proteins
in cancer with deregulation of extrinsec and intrinsic cell death
pathways. Clin Cancer Res. 23:1379–1387. 2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Schiliro C and Firestein BL: Mechanisms of
metabolic reprogramming in cancer cells supporting enhanced growth
and proliferation. Cells. 10(1056)2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Faubert B, Solmonson A and DeBerardinis
RJ: Metabolic reprogramming and cancer progression. Science.
368(eaaw5473)2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Greten FR and Grivennikov SI: Inflammation
and cancer. Triggers, mechanisms and consequences. Immunity.
51:27–41. 2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ,
Wu JS, Chen SJ and Tan BC: MiR31-5p-ACOX1 axis enhances tumorigenic
fitness in oral squamous cell carcinoma via the promigratory
Prostaglandin E2. Theranostics. 8:486–504. 2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Oshima S, Asai S, Seki N, Minemura C,
Kinoshita T, Goto Y, Kikkawa N, Moriya S, Kasamatsu A, Hanazawa T
and Uzawa K: Identification of tumor suppressive genes regulated by
miR-31-5p and miR-31-3p in head and neck squamous cell carcinoma.
Int J Mol Sci. 22(6199)2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Moskovitz J, Moy J and Ferris RL:
Immunotherapy for head and neck squamous cell carcinoma. Curr Oncol
Rep. 20(22)2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Li J, Xie Y, Wang X, Li F, Li S, Li M,
Peng H, Yang L, Liu C, Pang L, et al: Prognostic impact of
tumor-associated macrophage infiltration in esophageal cancer: A
meta-analysis. Future Oncol. 15:2303–2317. 2019.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Bras L, Driessen DAJJ, de Vries J, Festen
S, van der Laan BFAM, van Leeuwen BL, de Bock GH and Halmos GB:
Patients with head and neck cancer: Are they frailer than patients
with other solid malignancies? Eur J Cancer Care (Engl).
29(e13170)2020.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Sharma H, Sen S, Lo Muzio L, Mariggio MA
and Singh N: Antisense-mediated downregulation of anti-apoptotic
proteins induces apoptosis and sensitizes head and neck squamous
cell carcinoma cells to chemotherapy. Cancer Biol Ther. 4:720–727.
2005.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Farnebo L, Jedlinski A, Ansell A, Vainikka
L, Thunell LK, Grenman R, Johansson AC and Roberg K: Proteins and
single nucleotide polymorphisms involved in apoptosis, growth
control and DNA repair predict cisplatin sensitivity in head and
neck cancer cell lines. Int J Mol Med. 24:549–556. 2009.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Plavc G and Strojan P: Combining
radiotherapy with immunotherapy in definitive treatment of head and
neck squamous cell carcinoma: Review of current clinical trials.
Radiol Oncol. 54:377–393. 2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Goel B, Tiwari AC, Pandey RK, Singh AP,
Kumar S, Sinha A, Jain SK and Khattri A: Therapeutic approaches for
the treatment of head and neck squamous cell carcinoma-on update on
clinical trials. Transl Oncol. 21(101426)2022.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Fortpied C and Vinches M: The statistical
evaluation of treatment and outcomes in head and neck squamous cell
carcinoma clinical trials. Front Oncol. 9(634)2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Kawaguchi M, Kato H, Tomita H, Hara A,
Suzui N, Miyazaki T, Matsuyama K, Seishima M and Matsuo M: Magnetic
resonance imaging findings differentiating cutaneous basal cell
carcinoma from squamous cell carcinoma in the head and neck region.
Korean J Radiol. 21:325–331. 2020.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Weed DT, Zilio S, Reis IM, Sargi Z,
Abouyared M, Gomez-Fernandez CR, Civantos FJ, Rodriguez CP and
Serafini P: The reversal of immune exclusion mediated by Tadalafil
and an anti-tumor vaccine also induces PDL1 upregulation in
recurrent head and neck squamous cell carcinoma: Interim analysis
of a phase I clinical trial. Front Immunol. 10(1206)2019.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Basset-Seguin N and Herms F: Update in the
management of basal cell carcinoma. Acta DermVenereol.
100(adv00140)2020.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Marzuka AG and Book SE: Basal cell
carcinoma: Pathogenesis, epidemiology, clinical features,
diagnosis, histopathology and management. Yale J Bio Med.
88:167–179. 2015.PubMed/NCBI
|
|
93
|
Firnhaber JM: Basal cell and cutaneous
squamous cell carcinomas: Diagnosis and treatment. Am Fam
Physician. 102:339–346. 2020.PubMed/NCBI
|
